BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma.

On the CAR T front, bluebird bio Inc. (NASDAQ:BLUE) reported data from seven evaluable patients in the Phase I CRB-402 trial to treat relapsed or refractory MM following at least three prior regimens showing that its bb21217 led to a response rate of 85% per International Myeloma Working Group (IMWG) criteria. The responses included one stringent complete response (CR), three very good partial responses (VGPRs) and two PRs...